Companies
Promega Corporation
its NanoLuc luciferase platform continues to anchor new research, including a July 2025 study using NanoBiT/NanoBRET tags at endogenous gene loci for cancer protein-protein-interaction reporter cell lines, and a January 2026 paper engineering GFP-NanoLuc BRET fusion substrates for protease-activity detection.
- Country
- United States
bioluminescence
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
| marine-biotech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | 1 round of funding | zeliq.com |
| Capacity | Lyophilization capacity at Promega Madison more than doubled following a 2025/2026 expansion project | promega.com · promegaconnections.com |
| Certification | ISO 13485:2016 and ISO 14001 certified | promega.com |
| Regulatory approval | Maintains FDA compliance for IVD manufacturing at the Feynman Center facility | ewingcole.com |
| Production site | Multiple facilities in Madison, Wisconsin (e.g., 2800 Woods Hollow Road, 2780 Woods Hollow Drive, 5455 Nobel Drive, 5445 East Cheryl Parkway, 2617 Progress Rd, 5430 East Cheryl Parkway, 5500/5510 Nobel Drive, 3075 Sub-Zero Pkwy, 2800 Fish Hatchery Road) and international locations including California, China, and Korea | promega.com |
| Revenue | $450M annual revenue as of 2025 | zippia.com |
Independent sources: ewingcole.com · zeliq.com · zippia.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Automated nucleic acid extraction | analytics-pat | Low | → |
| Bioluminescence & marine fluorescent proteins | marine-biotech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.